Assets |
|
|
|
|
|
|
Cash and cash equivalents |
4,106,225 |
4,108,401 |
4,108,401 |
– |
|
– |
Balances with central banks |
10,557,688 |
10,557,688 |
10,557,688 |
– |
|
– |
Placements with banks |
6,691,381 |
6,691,381 |
6,691,381 |
– |
|
– |
Derivative financial instruments |
66,440 |
|
– |
– |
|
Included under other asset in regulatory reporting |
Other financial assets –
held-for-trading |
310,922 |
36,974,546 |
36,907,117 |
67,429 |
|
held for trading which are classified as AFS in published Financial Statements. |
Loans and receivables to banks |
10,984,266 |
– |
– |
– |
|
Stated under held to maturity in regulatory reporting |
Loans and receivables to
other customers |
213,675,866 |
213,027,200 |
196,846,026 |
– |
19,953,307 |
The impairment allowance for loans and advances on a collective and individual basis in accordance with LKAS 39 – Financial Instrument – Recognition and Measurement. The general and specific provisions are made in a accordance with Central Bank of Sri Lanka. The difference between the balance under SLFRS and previous GAAP. |
Financial investments –
available-for-sale (AFS)* |
56,866,054 |
– |
– |
– |
|
Classified into held to maturity and held for trading regulatory reporting |
Financial investments –
held-to-maturity* |
23,507,632 |
41,521,228 |
36,944,571 |
– |
4,576,657 |
are classified as AFS in published financial statements. |
Investments in subsidiaries |
167,036 |
202,305 |
202,305 |
– |
|
Investments in associates are included in regulatory reporting in addition to those in subsidiaries |
Investments in associates
and joint ventures |
790,270 |
– |
– |
– |
|
In regulatory reporting, the investments in joint ventures are stated under held to maturity |
Property, plant and equipment |
1,273,250 |
1,273,250 |
|
– |
|
– |
Goodwill and intangible assets |
498,084 |
498,084 |
– |
– |
498,084 |
|
Other assets |
3,612,228 |
4,391,724 |
4,518,513 |
– |
|
– |
Total assets |
333,107,342 |
319,245,807 |
298,018,347 |
67,429 |
24,932,164 |
– |
Liabilities |
|
|
|
|
|
|
Due to banks |
9,640,735 |
– |
– |
– |
– |
Included under Other Borrowings in regulatory reporting |
Derivative financial instruments |
367,435 |
– |
– |
– |
– |
Included under Other Liabilities in regulatory reporting |
Due to other customers* |
193,307,534 |
186,692,330 |
– |
– |
186,692,330 |
Interest payable on deposits are stated under Other Liabilities in regulatory reporting |
Other borrowings* |
41,319,591 |
74,092,476 |
– |
– |
74,092,476 |
Due to banks and Debt Securities Issued are included under this heading in regulatory reporting |
Debt securities issued* |
24,443,767 |
– |
– |
– |
– |
Included under Other Borrowings in regulatory reporting |
Current tax liabilities |
633,636 |
503,367 |
– |
– |
503,367 |
Taxes are computed based on different profits under each reporting method. |
Deferred tax liabilities |
1,194,027 |
1,016,856 |
– |
– |
1,016,856 |
Due to deferred tax adjustments on government securities classified as available for sale financial assets. |
Other liabilities |
5,120,981 |
13,486,355 |
– |
– |
13,486,355 |
Interest payable on Borrowing and deposits added to the Other Liabilities in regulatory reporting |
Due to subsidiaries* |
– |
– |
– |
– |
– |
– |
Subordinated term debts |
9,202,870 |
9,000,000 |
– |
– |
991,372 |
Regulatory reporting reports only the principal amount |
Total liabilities |
285,230,576 |
284,791,384 |
– |
– |
276,782,756 |
– |
Off–balance sheet liabilities |
|
|
|
|
|
|
Guarantees |
12,480,687 |
12,480,687 |
12,480,687 |
– |
|
– |
Performance bonds |
4,090,585 |
4,090,585 |
4,090,585 |
– |
|
– |
Letters of credit and acceptances |
15,098,107 |
15,098,107 |
15,098,107 |
– |
|
– |
Other contingent items
(bills on collection and
capital expenditure
approved by the board) |
2,305,466 |
2,305,466 |
|
– |
2,305,466 |
– |
Undrawn loan commitments |
62,852,575 |
62,852,575 |
62,852,575 |
– |
|
– |
Other commitments
(FX commitments) |
38,743,903 |
38,743,903 |
38,743,903 |
– |
|
– |
sheet liabilities |
135,571,324 |
135,571,324 |
133,265,858 |
– |
2,305,466 |
– |
Shareholders' equity |
|
|
|
|
|
|
Equity capital (stated capital)/
assigned capital of which
amount eligible for CET1 of
which amount eligible for AT1 |
4,715,814 |
4,715,814 |
– |
– |
|
– |
Retained earnings |
13,858,152 |
13,847,980 |
– |
|
|
Due to differences which arise in profits computed in previous GAAP and SLFRSs |
Accumulated other
comprehensive income |
13,298,686 |
– |
– |
– |
– |
Accumulated other comprehensive income is only applicable in published Financial Statements |
Other reserves |
16,004,114 |
15,890,629 |
– |
– |
15,784,114 |
Due to differences which arise in profits computed in previous GAAP and SLFRSs |
Total shareholders' equity |
47,876,766 |
34,454,475 |
– |
– |
15,784,114 |
– |